Home Blog of Signal Transduction Apoptosis Survivin

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Survivin

Drug Repositioning Identifies Six Drug Candidates for Systemic Autoimmune Diseases by Integrative Analyses of Transcriptomes from Scleroderma, Systemic Lupus Erythematosus, and Sjogren's Syndrome

186 views | Jan 25 2023

Elif Kubat Oktem et al. provided new insights and opens up new possibilities on both pathogenesis and treatment of systemic ADs through drug repositioning. [Read the Full Post]

Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent

82 views | Jan 25 2023

Jun Yang et al. identified a 27-gene module that was highly expressed in solid tumors, encoding actionable targets including EZH2 and BIRC5. [Read the Full Post]

Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1α and HIF-2α

274 views | Mar 23 2022

David Danielpour et al. hypothesized that a hypothetical hypoxia-inducer factor (HIF-X) repressed early signaling responses to YM155. [Read the Full Post]

miRNA‑218 targets multiple oncogenes and is a therapeutic target for osteosarcoma

422 views | Mar 22 2022

Kentaro Sato et al. found that miR‑218 showed a wider range of therapeutic efficacy compared with YM155, suggesting that miR‑218 should be evaluated as a treatment target. [Read the Full Post]

Emerging Effects of Sepantronium Bromide (YM155) on MOLT-4 Cell Line Apoptosis Induction and Expression of Critical Genes Involved in Apoptotic Pathways

404 views | Apr 11 2021

Kobra Shojaei Moghadam found that use of YM155 could be a potential drug therapy in T-ALL patients with promising effects on apoptosis induction. [Read the Full Post]

Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.

0 views | Sep 07 2017

Zhang W et al. provided evidence showing that YM155 could act as a small molecule survivin inhibitor on survivin-rich expressed SCC9 cells in culture as well as when grown as tumor in a xenograft model. [Read the Full Post]

Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells

0 views | Aug 30 2017

Zhang W et al. suggested that survivin could be further developed as a potential therapeutic agent for the treatment of survivin-rich expressed OSCC. [Read the Full Post]

Targeting survivin as a potential new treatment for chondrosarcoma of bone

0 views | May 19 2017

de Jong Y et al. found that survivin is important for chondrosarcoma survival and chondrosarcoma patients might benefit from survivin inhibition using YM155, for which TP53 mutational status can serve as a predictive biomarker. [Read the Full Post]

Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells

0 views | Dec 24 2016

Zhang W et al. suggested that survivin could be further developed as a potential therapeutic agent for the treatment of survivin-rich expressed OSCC. [Read the Full Post]

Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells

1944 views | Dec 03 2016

Zhang W et al. suggested that survivin could be further developed as a potential therapeutic agent for the treatment of survivin-rich expressed OSCC. [Read the Full Post]